Effect of Dietary Protein Restriction on Prognosis in Patients With Diabetic Nephropathy (LPD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01521910|
Recruitment Status : Completed
First Posted : January 31, 2012
Last Update Posted : January 31, 2012
|Condition or disease||Intervention/treatment||Phase|
|Type 1 Diabetes Mellitus With Diabetic Nephropathy||Dietary Supplement: low protein diet Dietary Supplement: normal protein diet||Not Applicable|
The study was a prospective, randomized, unmasked, controlled trial carried out at the Steno Diabetes Center. With concealed randomization the patients were (in blocks of two according to the level of GFR) assigned to receive either a usual-protein diet or a low-protein diet.
After randomization an iso-caloric low-protein diet of 0.6 g/kg/day was prescribed to patients in the low-protein diet group. The usual-pro tein diet consisted of the patients' pre-study diet.
The planned duration of follow-up was four years, scheduled visits every three-months. All patients gave complete history of medication, underwent examination of weight, urinary albumin-, sodium- and urea excretion, serum albumin, serum urea, hemoglobin, hemoglobin A1c, blood pressure, serum total-cholesterol, high-density lipoprotein (HDL) cholesterol.
GFR, serum triglycerides,calcium and phosphorous, anthropometric measurements, nutritional status and smoking habits were evaluated every six months.
Dietary protein intake was estimated on the basis of three consecutive 24-hour urine samples completed before each visit, using urinary excretion of urea nitrogen.
GFR was measured by plasma clearance of 51Cr-EDTA over a 4 hour period and standardized for 1.73m2 body surface area using the same surface for each patient during the study.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||82 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Effect of Dietary Protein Restriction on Prognosis in Patients With Diabetic Nephropathy|
|Study Start Date :||April 1995|
|Actual Primary Completion Date :||June 2000|
|Actual Study Completion Date :||June 2000|
|Experimental: Low protein diet||
Dietary Supplement: low protein diet
An iso-caloric low protein diet of 0.6 g/kg/day was prescribed during the whole study duration.
The same dietician gave nutritional advices at least every three months during the whole study period. Patients were also seen by the same doctor during each visit for the whole study period.
Supplementation of Calcium of 500mg/day.
Urine albumin losses >= 2 g/day wre replaced by increasing dietary protein on a gram-for-gram basis, only if the patient was compliant with the prescribed low-protein diet.
|Active Comparator: Normal protein diet||
Dietary Supplement: normal protein diet
The patients pre-study diet during the whole study period
Patients were also seen by the same doctor during each visit for the whole study period.
- Cumulative incidence of ESRD requiring dialysis or transplantation, and death [ Time Frame: 4 years ]
Cause of death was obtained from death certificate by an independent observer. Before the development of uremic symptoms, patients were referred to the department of nephrology at the University Hospital of Herlev or Rigshospitalet, when GFR deteriorated below 10 to 20 ML/min/1.73m2, where accepted criteria for initiation of dialysis and transplantation were applied on patients from both diet groups. Patients continued their scheduled visits and treatment in the study until the end of the four-year follow up.
This was assesed every 3 months until the end of the 4 year follow up period.
- Rate of decline of GFR [ Time Frame: 4 years ]rate of decline was measured if the patient had a minimum of one year of follow up and a minimum of 3 GFR measures during the study. All measures of GFR during the study period (including baseline) were used to calculate the rate of decline(the slopes) of GFR. GFR was measured every 6 months during the 4 years of follow up.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01521910
|Steno Diabetes Center|
|Gentofte, Denmark, 2820|
|Principal Investigator:||Henrik P Hansen, MD||Steno Diabetes Center Copenhagen|